Literature DB >> 33860186

Ethical Concerns about Psilocybin Intellectual Property.

Konstantin Gerber1, Inti García Flores2, Angela Christina Ruiz3, Ismail Ali4, Natalie Lyla Ginsberg4, Eduardo E Schenberg5.   

Abstract

Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33860186      PMCID: PMC8033603          DOI: 10.1021/acsptsci.0c00171

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  4 in total

1.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

2.  Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rights.

Authors:  Ian Vincent McGonigle
Journal:  J Law Biosci       Date:  2016-02-06

3.  Economic burden of relapse/recurrence in patients with major depressive disorder.

Authors:  Genevieve Gauthier; Lisa Mucha; Sherry Shi; Annie Guerin
Journal:  J Drug Assess       Date:  2019-05-24

4.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Authors:  Leor Roseman; David J Nutt; Robin L Carhart-Harris
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

  4 in total
  3 in total

Review 1.  Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.

Authors:  Sean J Belouin; Lynnette A Averill; Jack E Henningfield; Stephen N Xenakis; Ingrid Donato; Charles S Grob; Ann Berger; Veronica Magar; Alicia L Danforth; Brian T Anderson
Journal:  Neuropharmacology       Date:  2022-08-13       Impact factor: 5.273

Review 2.  Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.

Authors:  Snehal R Bhatt; Maya Armstrong; Tassy Parker; Marcello Maviglia; Rebecca Kass; Lawrence Leeman; Paul Romo; Douglas Ziedonis
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

3.  Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.

Authors:  Roberta Murphy; Hannes Kettner; Rick Zeifman; Bruna Giribaldi; Laura Kartner; Jonny Martell; Tim Read; Ashleigh Murphy-Beiner; Michelle Baker-Jones; David Nutt; David Erritzoe; Rosalind Watts; Robin Carhart-Harris
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.